Targeting therapeutic approaches and highlighting the potential role of nanotechnology in atopic dermatitis
- 23 February 2022
- journal article
- review article
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 29 (22) , 32605-32630
Abstract
Atopic dermatitis is a chronic as well as widespread skin disease which has significant influence on the life attributes of affected people and their families. Systemic immunosuppressive drugs can be utilised for effective care of disease, although they are often prescribed for rigorous disruption or disease that is complicated to manage. Therefore, topical applications of corticosteroids are considered the primary pharmacologic therapies for atopic dermatitis, and research recommends that these medications might be helpful in preventing disease flare-ups. However, topical medicine administration to deeper layers of skin is challenging because of the skin anatomic barrier that restricts deeper drug permeation, and also due to barrier function abnormalities in atopic dermatitis skin, which might result in systemic drug absorption, provoking systemic consequences. Hence, effective management of atopic dermatitis needs new, effective, safe and targeted treatments. Therefore, nanotechnology-based topical therapeutics have attracted much interest nowadays because of their tendency to increase drug diffusion and bioavailability along with enormous drug targeting potential to affected cells, and, thereby, reducing the adverse effects of medications. In this review, we mention different symptoms of atopic dermatitis, and provide an overview of the different triggering factors causing atopic dermatitis, with emphasis on its epidemiology, pathophysiology, clinical features and diagnostic, and preventive measures. This review discusses existing therapeutics for treating atopic dermatitis, and the newer approaches as well as the current classical pharmacotherapy of atopic dermatitis against new nanoparticle skin delivery systems. This review has also briefly summarised the recent patents and clinical status of therapeutic modalities for atopic dermatitis.Keywords
This publication has 194 references indexed in Scilit:
- CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adultsAllergy, Asthma & Clinical Immunology, 2013
- The Indoor Level of House Dust Mite Allergen Is Associated with Severity of Atopic Dermatitis in ChildrenJournal of Korean Medical Science, 2013
- Racial disparities in allergic outcomes in African Americans emerge as early as age 2 yearsClinical & Experimental Allergy, 2011
- Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's HealthJournal of Investigative Dermatology, 2011
- Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trialsBritish Journal of Dermatology, 2010
- The Influence of Pregnancy and Menstruation on the Deterioration of Atopic Dermatitis SymptomsAnnals of Dermatology, 2010
- Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease SeverityPediatrics, 2009
- The use of topical calcineurin inhibitors in dermatology: Safety concernsJournal of the American Academy of Dermatology, 2006
- Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitisNature Genetics, 2006
- Narrowband UVB phototherapy in skin conditions beyond psoriasisJournal of the American Academy of Dermatology, 2005